Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced today the completion of its acquisition of MacroGenics' GMP manufacturing operations, including the biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of $122.5 million. The acquisition was executed through Bora's wholly owned subsidiary Bora Biologics USA, LLC. Upon closing, Bora signed a long-term CDMO service agreement with MacroGenics.
With this transaction, Bora Biologics now operates 20,000 liters of single-use bioreactor drug substance manufacturing capacity across two active US sites: Rockville, Maryland and San Diego, California, along with a development facility in Zhubei, Taiwan. This expansion establishes a US biologics manufacturing platform that sponsors can rely on from development through licensed commercial supply, according to Bobby Sheng, Chairman and CEO of Bora Group.
"As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure," Sheng said. "Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities."
The Rockville facility adds significant capacity and regulatory credentials. Bora Biologics now supports more than four active commercial programs, with over 120 completed GMP batches supplying multiple global markets including the US, EU, Japan, Canada, and the UK, with fully integrated QC and analytical capabilities. Across its US network, Bora Biologics has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, all with clean results. The combined platform has supported more than 33 biologics and 15 biosimilars.
Bora Group intends to integrate its US drug substance capabilities with its existing sterile drug product capabilities over the next 12 to 18 months, offering a seamless, fully integrated development-through-commercial biologics solution. This move reduces offshore dependency and provides a domestically anchored infrastructure for biotech and pharmaceutical companies.
For more information about Bora Pharmaceuticals, visit https://www.bora-corp.com or https://www.boracdmo.com.
